• Alkermes plc (NASDAQ: ALKS) is advancing in the neuroscience and oncology sectors, with significant developments in sleep medicine.
• Executive VP Craig C. Hopkinson sold 5,000 shares, remaining with 61,740 shares, amidst the company's financial growth highlighted by a 32% increase in Lybalvi sales.
• The company's stock price reflects a modest increase, supported by a strong market capitalization and trading volume, alongside promising clinical trial results for Alixorexton.

Alkermes plc (NASDAQ: ALKS) is a biopharmaceutical company that focuses on developing innovative medicines in the fields of neuroscience and oncology. The company is making strides in the sleep medicine market, leveraging its acquisition of Avadel and the promising results from its Vibrance-2 study. Alkermes' strong legacy portfolio supports its rapid research and development expansion.

On January 8, 2026, Craig C. Hopkinson, Alkermes' Executive Vice President of Research and Development and Chief Medical Officer, sold 5,000 Ordinary Shares at $30 each. This transaction leaves him with 61,740 shares. The sale comes as Alkermes is experiencing growth, with Lybalvi sales increasing by 32% and favorable gross-to-net dynamics enhancing profitability.

Alkermes' stock is currently priced at $29.60, reflecting a 0.82% increase today. The stock has fluctuated between $29.06 and $30.08 during the trading day. Over the past year, it has seen a high of $36.45 and a low of $25.17. The company's market capitalization stands at approximately $4.89 billion, with a trading volume of 2,263,843 shares.

The success of Alixorexton in Phase 2 trials for narcolepsy and idiopathic hypersomnia, along with its clean safety profile, reduces the risk in Alkermes' clinical pipeline. This success, combined with the company's strategic acquisitions and strong portfolio, positions Alkermes well in the competitive biopharmaceutical landscape.